Transgene Biotek Current Share Price | Transgene Biotek Stock Screener
TRABI
Healthcare Service Provider
Transgene Biotek Current Stock Price Today
Live Share Price BSE
₹2.73
▲
0.04 (1.49%)
As of September 18, 2026, the live Transgene Biotek share price (BSE: TRABI) is ₹2.73, up 1.49% from the previous close, with shares trading between ₹2.67 and ₹2.91 in today's trading session, and a 52-week range of ₹1.97–₹4.28.
Browse TRABI income statement to support your investment research.
Use the Transgene Biotek stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Transgene Biotek Market Cap
₹21.02 Cr.
TRABI P/E Ratio (TTM)
-13.62
Transgene Biotek P/B Ratio
2.59
EPS (TTM)
₹-0.22
Dividend Yield
-
Debt to Equity
1.38
TRABI 52 Week High
₹4.28
Transgene Biotek 52 Week Low
₹1.97
Operating Margin
-560.00%
Profit Margin
-
TRABI Revenue (TTM)
-
EBITDA
-
Net Income
₹-1.00
Total Assets
₹144.00
Total Equity
₹8.00
Transgene Biotek Current Share Price Chart
Track the current Transgene Biotek share price and stock price with an interactive chart. Analyse TRABI price trends, trading volume, historical performance, and volatility across different timeframes — the complete Transgene Biotek stock quote in one place.
Transgene Biotek Company Profile - Fundamental Screener
Screen Transgene Biotek company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for TRABI shares.
Sector
Healthcare Services
Industry
Healthcare Service Provider
Sub-Sector
Healthcare Service Provider
Segment
E
ISIN
INE773D01018
Transgene Biotek Balance Sheet Screener
Screen TRABI balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 144 | 144 | 142 | 142 | 147 | 157 | 167 | 177 | 187 | 198 |
| Current Assets | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Fixed Assets | 10 | 8 | 6 | 6 | 11 | 21 | 31 | 41 | 51 | 61 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 122 | 121 | 121 | 121 | 121 | 121 | 120 | 120 | 120 | 128 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 8 | 10 | 11 | 11 | 17 | 22 | 33 | 44 | 52 | 59 |
| Share Capital | 76 | 76 | 76 | 76 | 76 | 76 | 76 | 76 | 76 | 76 |
| Reserves & Surplus | -67 | -66 | -65 | -64 | -58 | -54 | -43 | -32 | -23 | -17 |
Transgene Biotek Income Statement Screener - Profit & Revenue Analysis
Screen Transgene Biotek income statement and profit fundamentals.
Analyze TRABI quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Transgene Biotek share price evaluation.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Profit % | -560.00% | -100.00% | -675.00% | -280.00% | -160.00% | -120.00% | -520.00% | -820.00% | -133.00% | -113.00% | 0.00% | -120.00% | -240.00% | -200.00% | -56.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -1 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | 0 | 0 | 0 | -3 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -1 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | 0 | 0 | 0 | -3 |
| EPS | -0.06 | -0.05 | -0.09 | -0.06 | -0.05 | -0.05 | -0.04 | 0.03 | -0.01 | -0.01 | -0.19 | -0.02 | -0.02 | -0.02 | -0.34 |
Transgene Biotek Cash Flow Screener - Liquidity Fundamentals
Screen TRABI cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1 | 0 | 0 | 0 | 0 | 0 | -2 | -1 | 0 | 7 |
| Investing Activities | -2 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | -7 |
| Financing Activities | 1 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | 0 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Transgene Biotek Shareholding Pattern Screener
See Transgene Biotek shareholding pattern with promoter, FII, and DII holdings.
Check Transgene Biotek promoter holding and ownership changes for TRABI on TickJournal.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 71.81% | 71.70% | 71.88% | 71.89% | 71.85% | 71.85% | 71.45% | 71.75% |
| Other Holding | 4.55% | 4.66% | 4.48% | 4.48% | 4.51% | 4.51% | 4.92% | 4.61% |
| Shareholder Count | 13,767 | 13,817 | 13,583 | 13,475 | 13,461 | 13,545 | 12,426 | 12,766 |
Transgene Biotek Share Dividend Screener - Share Yield Analysis
Check Transgene Biotek dividend history with payout and yield data.
View Transgene Biotek dividend details including ex-dates and amounts for TRABI stock.
Transgene Biotek Stock Index Membership
See which indices include Transgene Biotek stock.
Check TRABI index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Transgene Biotek Market Events Screener - Corporate Actions
Get Transgene Biotek corporate actions including splits, bonuses, and buybacks.
Check Transgene Biotek stock events that may affect TRABI share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-12-30 | 2026-12-30 | Annual General Meeting | NA | -28.21% |
| 2026-08-07 | 2026-08-07 | Quarterly Result Announcement | NA | -2.35% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 3.22% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | 16.36% |
| 2025-12-07 | 2025-12-07 | Extraordinary General Meeting | NA | 0.00% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 4.28% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | 2.14% |
| 2025-05-07 | 2025-05-07 | Quarterly Result Announcement | NA | -10.03% |
| 2025-01-24 | 2025-01-24 | Quarterly Result Announcement | NA | 4.20% |
| 2024-12-05 | 2024-12-05 | Annual General Meeting | NA | 0.74% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | -3.82% |
| 2023-12-30 | 2023-12-30 | Annual General Meeting | NA | 58.94% |
Transgene Biotek Competitors Screener - Peer Comparison
Screen TRABI competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Dr. Lal Path Labs | 32,002 | 58.88 | 2,864 | 12.11% | 510 | 53.50 |
| Vijaya Diagnostic Centre | 15,455 | 82.34 | 835 | 19.34% | 173 | 58.30 |
| Metropolis Healthcare | 12,139 | 61.01 | 1,671 | 24.15% | 191 | 54.18 |
| Thyrocare Technologies | 8,749 | 50.45 | 846 | 20.48% | 163 | 38.82 |
| Nephrocare Health Services | 7,680 | 88.34 | 1,023 | 32.93% | 77 | 68.67 |
| Krsnaa Diagnostics | 1,784 | 18.74 | 773 | 4.05% | 106 | 47.23 |
| Suraksha Diagnostic | 1,686 | 48.71 | 314 | 22.55% | 31 | 55.15 |
| 3B BlackBio DX | 1,219 | 22.06 | 142 | 27.17% | 61 | 56.62 |
| One Global Service Provider | 1,056 | 14.36 | 498 | 237.06% | 69 | 45.33 |
| Health X Platform | 980 | -37.45 | 1,319 | 12.68% | -3 | 55.59 |
Transgene Biotek Company Announcements - News Screener
Screen TRABI latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-08-11 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-07 | 1)The Board Considered And Approved The Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June 2026. 2) The Board Considered And Approved The Limited Review Report (Standalone & Consolidated) Of The Compa | - |
| 2026-08-07 | Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On August 07 2026. | - |
| 2026-07-23 | Board Meeting Intimation for Intimation Of The Board Meeting. | - |
| 2026-07-22 | Compliance-57 (4) : Prior intimation to the beginning of the quarter | - |
| 2026-07-22 | Statement Of Deviation & Variation | - |
| 2026-07-22 | Compliance-57 (5) : intimation after the end of quarter | - |
| 2026-07-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-20 | Closure of Trading Window | - |
| 2026-06-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-29 | Outcome Of Board Meeting And Submission Of Audited Financial Results For The Fourth Quarter And Financial Year Ended March 31 2026 | - |
| 2026-05-29 | Board Meeting Outcome for Outcome Of Board Meeting And Submission Of Audited Financial Results For The Fourth Quarter And Financial Year Ended March 31 2026 | - |
| 2026-05-15 | Board Meeting Intimation for Intimation Of The Board Meeting Of The Company - This Is To Inform You That A Meeting Of Board Of Directors Of The Company Will Be Held On Friday 29Th May 2026. | - |
| 2026-04-13 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-13 | Intimation Of Non-Applicability Of Regulation 32(1) Of SEBI Listing Obligations And Disclosure Requirements) Regulations 2015 For The Quarter Ended On 31St March 2026. | - |
| 2026-04-13 | Compliance-57 (4) : Prior intimation to the beginning of the quarter | - |
| 2026-04-13 | Compliance-57 (5) : intimation after the end of quarter | - |
| 2026-04-13 | Compliance Certificate Pursuant To Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015. | - |
| 2026-04-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-24 | Closure of Trading Window | - |